GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reneo Pharmaceuticals Inc (NAS:RPHM) » Definitions » Total Current Liabilities

Reneo Pharmaceuticals (Reneo Pharmaceuticals) Total Current Liabilities : $2.81 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Reneo Pharmaceuticals Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Reneo Pharmaceuticals's total current liabilities for the quarter that ended in Mar. 2024 was $2.81

Reneo Pharmaceuticals Total Current Liabilities Historical Data

The historical data trend for Reneo Pharmaceuticals's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reneo Pharmaceuticals Total Current Liabilities Chart

Reneo Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
2.94 4.58 6.20 7.12 18.18

Reneo Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.48 13.74 13.56 18.18 2.81

Reneo Pharmaceuticals Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Reneo Pharmaceuticals's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=13.898+0.331
+Other Current Liabilities+Current Deferred Liabilities
=3.948+0
=18.18

Reneo Pharmaceuticals's Total Current Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=1.313+0.331
+Other Current Liabilities+Current Deferred Liabilities
=1.17+0
=2.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Reneo Pharmaceuticals Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Reneo Pharmaceuticals's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Reneo Pharmaceuticals (Reneo Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reneo Pharmaceuticals Inc (NAS:RPHM) » Definitions » Total Current Liabilities
Comparable Companies
THRD XERS PGEN AVIR NRIX EYPT QURE NUVB OVID OCUL OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
18575 Jamboree Road, Suite 275-S, Irvine, CA, USA, 92612
Website
https://www.reneopharma.com
Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
Executives
Ashley Hall officer: Chief Development Officer C/O ESPERION THERAPEUTICS INC., 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI 48108
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Niall O'donnell director C/O RIVERVEST VENTURE PARTNERS, 101 SOUTH HANLEY RD., STE 1850, ST. LOUIS MO 63105
Michael Cruse officer: Senior VP, Corporate Operation C/O RENEO PHARMACEUTICALS, INC., 12230 EL CAMINO REAL, SUITE 230, SAN DIEGO CA 92130
Roshawn A. Blunt director 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
Jennifer Lam officer: VP of Finance & Administration C/O RENEO PHARMACEUTICALS, INC., 18575 JAMBOREE ROAD, SUITE 275-S, IRVINE CA 92612
Paul W. Hoelscher director 1 HORIZON WAY, C/O HORIZON THERAPEUTICS, INC., DEERFIELD IL 60015
Vineet R. Jindal officer: Chief Financial Officer C/O RENEO PHARMACEUTICALS, INC., 12230 EL CAMINO REAL, SUITE 230, SAN DIEGO CA 92130
Gregory J. Flesher director, officer: President and CEO 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Bali Muralidhar director C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE IL 60077
Wendy S. Johnson officer: Chief Development Officer 800 E. LEIGH STREET, SUITE 209, RICHMOND VA 21219
New Enterprise Associates 15, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Rivervest Venture Fund Iii (ohio), L.p. 10 percent owner 11000 CEDAR AVENUE, SUITE 100, CLEVELAND OH 44106-3502
Rivervest Venture Fund Iii, L.p. 10 percent owner 7733 FORSYTH BOULEVARD, ST. LOUIS MO 63105
Stacey Denenberg Seltzer director C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106